Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
600 participants
OBSERVATIONAL
2023-11-01
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of Biomarkers in Lymph Node Tissue
NCT04228796
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma
NCT00981097
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881
Sample Collection and Tracking for the Developmental Therapeutics Clinic
NCT03269578
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
NCT05676450
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Currently the study accrued 108 paired TBBs and 3BMBs, 9 TBBs, and 64 corresponding blood samples for dd-cfDNA test.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Natera, Inc.
INDUSTRY
One Lambda
UNKNOWN
University of Alberta
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philip F Halloran, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Alberta Transplant Applied Genomics Centre, University of Alberta
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Joseph's Hospital and Medical Center 350 West Thomas Road, Floor 8HLT
Phoenix, Arizona, United States
Division of Pulmonary, Critical Care and Sleep Medicine, University of Florida, College of Medicine
Gainesville, Florida, United States
USF Health, Morsani College of Medicine, 12901 Bruce B. Downs Blvd. MDC40
Tampa, Florida, United States
Indiana University Methodist Hospital 1812 N. Capitol Ave Suite W131L
Indianapolis, Indiana, United States
Johns Hopkins Interventional Pulmonology, Sheikh Zayed Tower, Room 7125L, 1800 Orleans Street
Baltimore, Maryland, United States
Division of Pulmonary, Allergy & Critical Care Medicine Columbia University Irving Medical Center
New York, New York, United States
The Ohio State University Wexner Medical Center, 410 W 10th Ave
Columbus, Ohio, United States
BAYLOR SCOTT & WHITE RESEARCH INSTITUTE , 3409 Worth Street
Dallas, Texas, United States
UT Southwestern Medical Center, 5939 Harry Hines Blvd.
Dallas, Texas, United States
Houston Methodist Lung Transplant Center, 6550 Fannin St., SM1001
Houston, Texas, United States
UT Health San Antonio 7703 Floyd Curl Drive, MSC: 7858
San Antonio, Texas, United States
The Alfred Hospital, Monash University
Melbourne, , Australia
Department of Thoracic Surgery, Medical University of Vienna
Vienna, , Austria
Department of Medicine, University of Alberta
Edmonton, Alberta, Canada
Alberta Transplant Applied Genomics Centre, University of Alberta
Edmonton, Alberta, Canada
University Health Network, Toronto General Hospital
Toronto, Ontario, Canada
Motol University Hospital, V Uvalu 84
Prague, , Czechia
Charles University/Hospital Motol
Prague, , Czechia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00048176
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.